Resources

In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

BIA and Japan Bioindustry Association signed an MOU, agreeing to work together to connect the two countries’ life sciences and biotech ecosystems to accelerate medical innovation and the commercialisation of engineering biology.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Medannex's novel therapy MDX-124, for the treatment of biliary tract cancer (BTC). The FDA’s decision is based on emerging clinical data from the ongoing first-in-human Phase 1b ATTAINMENT clinical trial, which shows promising efficacy signals in patients treated with MDX-124 monotherapy. Durable disease control and tumour shrinkage have been observed in several BTC patients, with no significant side effects. 

Arecor Therapeutics plc has signed a co-development agreement with Sequel Med Tech LLC to combine AT278 (500U/mL) with Sequel’s twiist™ Automated Insulin Delivery (AID) system powered by Tidepool, and a royalty financing agreement with Ligand which will raise non-dilutive capital of up to $11 million (£8.2 million).

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

MoU will explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

Shaun Grady is becoming BIA chair, effective from January 2026, in another week of innovation for our sector.

MSD's record-breaking $10 billion acquisition of Verona Pharma illustrates the potential of our sector, but also is a reminder of the need to strengthen UK capital markets.

In this article, Kate Barclay, Skills Strategy Consultant at BIA, outlines new changes to UK immigration law and how they will impact the life sciences sector. Prepared in collaboration with legal experts at Eversheds-Sutherland LLP.

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026

Brainomix and 3DR Labs announced a new strategic partnership to support acute stroke care in the US through the clinically validated and FDA-cleared Brainomix 360 Stroke.

We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar. 

WHO members adopted the pandemic preparedness accord as an international treaty at the World Health Assembly. In this blog, Senior Policy and Public Affairs Manager Linda Bedenik looks at what the agreement means for life sciences.

Poolbeg Pharma announces that the US Food and Drug Administration has granted Orphan Drug Designation to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome.